Patients who suffer from the advanced form of age-related macular degeneration benefit from utilizing the ForeseeHome monitoring device to help preserve their visual acuity. The National Eye Institute led the AREDS2 HOME Study to determine the value of using the ForeseeHome monitoring device compared with standard care alone for the detection of the progression of macular degeneration to the "wet" phase.
Forty-four clinical centers across the United States took part in the HOME study with 1,520 participants who were at high risk for developing the wet form of macular degeneration. AMD patients are able to use the ForeseeHome device if it is prescribed by their eye care professional and is used to help patients manage their AMD at home between their regularly scheduled office visits.
Researchers found that 87% of the eyes that were monitored with the ForeseeHome device kept a visual acuity of 20/40 or better compared to the eyes that only received standard care which had only 62% measuring 20/40 or better. In addition, when the wet form of macular degeneration was detected in participants in the ForeseeHome device group, those participants lost fewer letters on visual acuity testing.*